Amount of closing payment receivable under agreement.

No definition available.

Name:	tbph_CollaborativeArrangementClosingConsiderationPayment
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The percentage of economic interest in any future payments made under the strategic alliance agreement and under the portion of the collaboration agreement.

+ References

No definition available.

+ Details

Name:	tbph_EconomicInterestPercentage
Namespace Prefix:	tbph_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of input used to measure equity method investment, contingent consideration.

+ References

No definition available.

+ Details

Name:	tbph_EquityMethodInvestmentContingentConsiderationMeasurementInput
Namespace Prefix:	tbph_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of future contingent milestone and royally assets.

+ References

No definition available.

+ Details

Name:	tbph_FutureContingentMilestoneAndRoyaltyAssets
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of right to receive royalty is transferred.

+ References

No definition available.

+ Details

Name:	tbph_RoyaltyRevenuePercentage
Namespace Prefix:	tbph_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from the issuance of common limited partners units during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=tbph_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=tbph_TheravanceRespiratoryCompanyLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tbph_PurchaseAgreementToSellUnitsInTheravanceRespiratoryCompanyLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tbph_TheravanceRespiratoryCompanyLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Discontinued Operations (Details) $ in Thousands	1 Months Ended
Discontinued Operations (Details) $ in Thousands	Jul. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Theravance Respiratory Company, LLC
Future contingent milestone and royalty assets		$ 194,200	$ 194,200
Royalty Pharma \| Disposed of by Sale \| TRC \| Measurement Input, Discount Rate [Member]
Theravance Respiratory Company, LLC
Equity method investment, contingent consideration	7.83
Royalty Pharma \| Purchase Agreement to Sell Units in Theravance Respiratory Company, LLC
Theravance Respiratory Company, LLC
Percentage of Right to Receive Royalty Transferring	85
Proceeds from sale of units.	$ 1,100,000
Consideration Receivable at closing	$ 250,000
TRC
Theravance Respiratory Company, LLC
Percentage of economic interest	85.00%